{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chu D"],"funding":["National Institutes of Health","NIAMS NIH HHS","NIH HHS"],"pagination":["2676-2687"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12048083"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["64(5)"],"pubmed_abstract":["<h4>Objectives</h4>To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of LN progression or disease resolution across a 1-year study.<h4>Methods</h4>Serum and urine samples from biopsy proven LN subjects (n = 122) were prospectively collected over the course of a year at 3- or 6-month intervals (weeks 0, 12, 26 and 52) across multiple study sites and assessed for soluble ALCAM and CD6 levels. Urine creatinine from the same urine sample was used to normalize the levels of urinary ALCAM and urinary CD6. Measured levels of serum and urine ALCAM and CD6 were then analysed against disease metrics cross-sectionally and longitudinally.<h4>Results</h4>Cross-sectional analysis at baseline revealed that urinary ALCAM significantly correlated with urine protei"],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis."],"pmcid":["PMC12048083"],"funding_grant_id":["UH2 AR067689","UH2 AR067679","UH2-AR067691","UH2- AR067688","UH2 AR067694","UH2-AR067681","UH2 AR067681","UH2-AR067694","UH2 AR067676","UH2 AR067688","UH2 AR067677","UH2 AR067685","UM2 AR067678","UH2-AR067690","UH2-AR067677","UH2-AR067689","UH2-AR067679","UH2 AR067690","UH2 AR067691","UH2-AR067685","UH2-AR067676","UM2- AR067678"],"pubmed_authors":["Zhang F","Fung M","Wofsy D","Davidson A","Raychaudhuri S","Guthridge J","James J","Buyon JP","Anolik J","Tuschl T","Rao D","Payan-Schober F","Pendergraft W","Cunningham M","Connery S","Furie R","Ampudia J","Park M","Dall'Era M","Hoover P","Accelerating Medicines Partnership: RA/SLE Network","Kretzler M","Hacohen N","Utz PJ","Der E","Brenner M","Berthier C","Waguespack D","Kalunian K","Petri M","McCune W","Clancy R","Arazi A","Maecker H","Chu D","McMahon M","Apruzzese W","Gupta R","Connelly S","Ng CT","Slowikowski K","Fava A","Mohan C","Massarotti E","Pichavant M","Kamen D","Schwartz N","Goldman D","Buyon J","Hsu R","Kado R","Fonseka C","Putterman C","Suryawanshi H","Hildeman D"],"additional_accession":[]},"is_claimable":false,"name":"Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.","description":"<h4>Objectives</h4>To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of LN progression or disease resolution across a 1-year study.<h4>Methods</h4>Serum and urine samples from biopsy proven LN subjects (n = 122) were prospectively collected over the course of a year at 3- or 6-month intervals (weeks 0, 12, 26 and 52) across multiple study sites and assessed for soluble ALCAM and CD6 levels. Urine creatinine from the same urine sample was used to normalize the levels of urinary ALCAM and urinary CD6. Measured levels of serum and urine ALCAM and CD6 were then analysed against disease metrics cross-sectionally and longitudinally.<h4>Results</h4>Cross-sectional analysis at baseline revealed that urinary ALCAM significantly correlated with urine protei","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-04T10:33:51.274Z","creation":"2026-06-02T03:08:17.98Z"},"accession":"S-EPMC12048083","cross_references":{"pubmed":["39404817"],"doi":["10.1093/rheumatology/keae559"]}}